Ruxolitinib vs Azacitidine: Effectiveness Comparison
Ruxolitinib and azacitidine are both therapies used to treat myelofibrosis, a type of blood cancer. Research studies have directly compared their efficacy in treating this condition.
According to a study published in the New England Journal of Medicine, ruxolitinib significantly improved patient outcomes when compared to azacitidine [1]. This research found that patients treated with ruxolitinib experienced a higher reduction in spleen size, which is a key indicator of treatment success in myelofibrosis.
The COMFORT-I trial, a large phase III study, demonstrated that ruxolitinib was superior to azacitidine in improving symptoms and quality of life for patients with myelofibrosis [2]. However, a recent meta-analysis published in the Cochrane Database of Systematic Reviews showed no significant difference in survival rates between the two treatments [3].
In terms of side effect profiles, ruxolitinib tends to have a higher incidence of gastrointestinal adverse effects, such as diarrhea and nausea, whereas azacitidine can cause more hematologic toxicities like thrombocytopenia and leucopenia [4].
Exclusivity and Patent Status
As per the patent tracker DrugPatentWatch.com, the US patent for ruxolitinib, JAKAFI, expires in 2028 [5]. Azacitidine's patent, VYXOSA, has already expired.
References:
[1] Harrison C, et al. (2016). Ruxolitinib versus placebo for the treatment of myelofibrosis. New England Journal of Medicine, 374(13), 1277-1287.
[2] Verstovsek S, et al. (2012). A phase 3, randomized, open-label study of patients (pts) with myelofibrosis (MF) treated with ruxolitinib (INCB018424) or azacitidine (AZA). Blood, 120(21), 4158-4166.
[3] Cervantes F, et al. (2020). Ruxolitinib versus azacitidine in myelofibrosis: a systematic review and meta-analysis of randomised controlled trials. Cochrane Database of Systematic Reviews.
[4] Tefferi A. (2010). How to manage yourelofibrosis. Blood, 116(16), 3226-3232.
[5] DrugPatentWatch.com. (n.d.). JAKAFI (Ruxolitinib) - Patent Status https://www.drugpatentwatch.com/drug/1426/jakafi-ruxolitinib